Last $1.32 USD
Change Today -0.13 / -8.97%
Volume 3.0M
ZGNX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

zogenix inc (ZGNX) Snapshot

Open
$1.41
Previous Close
$1.45
Day High
$1.46
Day Low
$1.32
52 Week High
02/13/14 - $5.19
52 Week Low
07/31/14 - $1.32
Market Cap
184.2M
Average Volume 10 Days
1.4M
EPS TTM
$-0.67
Shares Outstanding
139.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZOGENIX INC (ZGNX)

zogenix inc (ZGNX) Details

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders and pain. The company’s commercial product includes Zohydro, a single-entity extended-release hydrocodone for the treatment of moderate to severe chronic pain. It also develops Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.

114 Employees
Last Reported Date: 03/7/14
Founded in 2006

zogenix inc (ZGNX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $449.3K
President and Director
Total Annual Compensation: $370.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $335.1K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $335.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $71.5K
Compensation as of Fiscal Year 2013.

zogenix inc (ZGNX) Key Developments

Zogenix, Inc. Appoints David Brushwood to External Safe Use Board

Zogenix, Inc. announced that David Brushwood, J.D., R.Ph., recently-retired Professor Emeritus of Pharmaceutical Outcomes and Policy at the University of Florida, College of Pharmacy, has joined the company's External Safe Use Board. This group of independent experts is responsible for providing thorough feedback and recommendations regarding the use of Zohydro(R) ER (hydrocodone bitartrate) Extended-Release Capsules, CII.

Zogenix Provides Update on Development of Abuse Deterrent Formulations of Zohydro(R) ER

Zogenix, Inc. announced an update on its development programs focused on the introduction of abuse deterrent formulations of Zohydro(R) ER (hydrocodone bitartrate) Extended-Release Capsules, CII. Zohydro ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Following a recent meeting with the U.S. Food and Drug Administration (FDA), Zogenix expects to file a supplemental new drug application (sNDA) by October 2014 for a next-generation formulation of Zohydro ER Extended-Release Capsules designed to make it more difficult to abuse by injection or nasal administration. If approved, this new formulation could be available to prescribers in early 2015. The company will continue to characterize the product's abuse deterrent properties with the goal of further amending the labeling for Zohydro ER Extended-Release Capsules in 2015 to include abuse deterrence claims consistent with the FDA's current draft Guidance for Industry, Abuse-Deterrent Opioids -- Evaluation and Labeling.

Zogenix, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 10:00 AM

Zogenix, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 10:00 AM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States. Speakers: Ann D. Rhoads, Chief Financial Officer, Principal Accounting Officer, Executive Vice President, Treasurer and Secretary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZGNX:US $1.32 USD -0.13

ZGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eternity Healthcare Inc $0.13 USD +0.055
View Industry Companies
 

Industry Analysis

ZGNX

Industry Average

Valuation ZGNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.0x
Price/Book 83.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOGENIX INC, please visit www.zogenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.